In:
International Journal of Cancer, Wiley, Vol. 138, No. 10 ( 2016-05-15), p. 2499-2509
Abstract:
What's new? Few markers can predict patient survival from the time of early disease dissemination in metastatic breast cancer (MBC), the cause of most breast cancer deaths. However, it may be possible to improve survival and quality of life in MBC with prognostic markers that are noninvasive and more specific. A promising candidate is hyaluronic acid (HA), elevated plasma levels of which are shown here to be significantly associated with poor prognosis of MBC patients. HA plasma levels decreased in parallel with treatment response, suggesting that HA may also be an effective real‐time marker for MBC treatment‐monitoring.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink